Genia Technologies has landed a $5.3 NIH grant to advance its genome sequencing technology. The company will use the money in its work with partners at Columbia University and Harvard Medical school to fund more development of NanoTag, its nanopore-based DNA sequencing platform.
Logistical and manufacturing complexities have tempered hype around personalized cancer vaccines for years, with skeptics questioning the viability of removing, reprogramming and reintroducing immune cells on commercial scales. An implantable vaccine aims to overcome these problems.
Harvard Medical School and Danish researchers developed a new MRI diagnostic technique that can help determine how well patients with aggressive brain cancer will respond to a particular form of treatment.
Investigators at the Harvard Stem Cell Institute have discovered a hormone with the ability to produce beta cells--the insulin-producing cells found in the pancreas that are lost in diabetes--that could potentially treat type 2 diabetes more effectively.
Scientists from some of the country's leading research institutions think they've found a trigger for autoimmune disorders like multiple sclerosis, which have been increasing in frequency over the past few decades.
Israel's NeuroQuest will begin a clinical validation trial this summer for a new blood diagnostic test designed for early detection of Alzheimer's, ALS and other neurodegenerative diseases.
After news of cell transplants making blind mice see, U.S. researchers have used an experimental drug to make deaf mice hear.
The 2008 Fierce 15 biotech Genocea Biosciences has picked up a key endorsement and a sizeable amount of cash today as the Bill & Melinda Gates Foundation joined a bevy of venture investors backing a $30 million C round.
Scientists have spent decades researching potential drugs to serve as male contraceptives without much success. Yet now a mouse study sheds light on how a compound initially created to combat cancer was able to cut sperm counts in male mice without ruining their chances of siring future offspring.
There is no preventive vaccine or cure, but Genocea Biosciences has a prophylactic HSV-2 vaccine moving into a first in-human clinical trial in third quarter 2012, Chip Clark, president and CEO told FierceVaccines at BIO 2012. Seth Hetherington, CMO, was also at the meeting, presenting in the session "Therapeutic Vaccines Against Chronic Infectious Diseases: Vaccines versus Microbes Part 2."